Geovax Labs (Geovax Labs) Beneish M-Score : 0.00 (As of May. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Geovax Labs's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Geovax Labs was 25.57. The lowest was -13.89. And the median was -6.62.

Geovax Labs Beneish M-Score Historical Data

The historical data trend for Geovax Labs's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geovax Labs Beneish M-Score Chart

Geovax Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

-12.46

-1.15

-8.75

25.57

Geovax Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Beneish M-Score	Get a 7-Day Free Trial															25.57	-	-	-	-

Competitive Comparison of Geovax Labs's Beneish M-Score

For the Biotechnology subindustry, Geovax Labs's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geovax Labs's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Geovax Labs's Beneish M-Score falls into.

Geovax Labs Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Geovax Labs for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Dec23) TTM:

Last Year (Dec22) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $7.89 Mil.
Total Assets was $9.28 Mil.
Property, Plant and Equipment(Net PPE) was $0.21 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.07 Mil.
Selling, General, & Admin. Expense(SGA) was $6.02 Mil.
Total Current Liabilities was $3.52 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Net Income was -7.592 + -8.409 + -5.928 + -4.038 = $-25.97 Mil.
Non Operating Income was 0 + 0 + 0 + 0.232 = $0.23 Mil.
Cash Flow from Operations was -10.278 + -5.096 + -6.037 + -3.763 = $-25.17 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0.082 = $0.08 Mil.
Gross Profit was 0 + 0 + 0 + 0.082 = $0.08 Mil.
Total Current Assets was $28.94 Mil.
Total Assets was $31.35 Mil.
Property, Plant and Equipment(Net PPE) was $0.24 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.06 Mil.
Selling, General, & Admin. Expense(SGA) was $4.99 Mil.
Total Current Liabilities was $4.75 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 0)	/	(0 / 0.082)
	=		/	0
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0.082 / 0.082)	/	(0 / 0)
	=	1	/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (7.886 + 0.21) / 9.283)	/	(1 - (28.939 + 0.235) / 31.348)
	=	0.127868	/	0.069351
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0.082
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(0.056 / (0.056 + 0.235))	/	(0.073 / (0.073 + 0.21))
	=	0.19244	/	0.257951
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(6.022 / 0)	/	(4.986 / 0.082)
	=		/	60.804878
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0 + 3.52) / 9.283)	/	((0 + 4.748) / 31.348)
	=	0.379188	/	0.151461
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-25.967 - 0.232	-	-25.174)	/	9.283
	=	-0.110417

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Geovax Labs Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Geovax Labs's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » Beneish M-Score

Comparable Companies

Traded in Other Exchanges

E8L:Germany E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Executives

Mckee Kelly T. Jr.	officer: Chief Medical Officer	233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
David A Dodd	director	C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds	officer: Chief Financial Officer	TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Jayne Morgan	director	1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase	director	28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey	officer: VP, Business Development	16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas	director	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr	director	2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally	director
Farshad Guirakhoo	officer: Sr VP, Research & Development	39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi	director	10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson	other: Chair, Scientific Adv Brd	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman	officer: VP, Research & Development	1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas	director	123 JOAN DRIVE, BARRINGTON IL 60010